Literature DB >> 12200193

Influence of neuromelanin on oxidative pathways within the human substantia nigra.

K L Double1, D Ben-Shachar, M B H Youdim, L Zecca, P Riederer, M Gerlach.   

Abstract

Neuromelanin (NM) is a dark-coloured pigment produced in the dopaminergic neurons of the human substantia nigra (SN). The function of NM within the pigmented neurons is unknown but other melanins are believed to play a protective role via attenuation of free radical damage. Experimental evidence suggests that NM may also exhibit this characteristic, possibly by directly inactivating free radical species or via its ability to chelate transition metals, such as iron. Increased tissue iron, however, may saturate iron-chelating sites on NM and a looser association between iron and NM may result in an increased, rather than decreased, production of free radical species. The death of NM-pigmented neurons in Parkinson's disease (PD) is associated with both a measurable increase in tissue iron concentrations and indices of free radical mediated damage, suggesting that NM is involved in the aetiology of this disorder. As yet, it is unknown whether NM in the parkinsonian brain differs to that found in healthy tissue and thus may fulfil a different role within this tissue.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12200193     DOI: 10.1016/s0892-0362(02)00218-0

Source DB:  PubMed          Journal:  Neurotoxicol Teratol        ISSN: 0892-0362            Impact factor:   3.763


  28 in total

Review 1.  The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy.

Authors:  Alessandra Gaeta; Robert C Hider
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

Review 2.  Genetics of iron regulation and the possible role of iron in Parkinson's disease.

Authors:  Shannon L Rhodes; Beate Ritz
Journal:  Neurobiol Dis       Date:  2008-07-11       Impact factor: 5.996

3.  Identification of L-ferritin in neuromelanin granules of the human substantia nigra: a targeted proteomics approach.

Authors:  Florian Tribl; Esther Asan; Thomas Arzberger; Thomas Tatschner; Elmar Langenfeld; Helmut E Meyer; Gerhard Bringmann; Peter Riederer; Manfred Gerlach; Katrin Marcus
Journal:  Mol Cell Proteomics       Date:  2009-03-24       Impact factor: 5.911

Review 4.  Neuromelanin of the human substantia nigra: an update.

Authors:  Fabio A Zucca; Emy Basso; Francesca A Cupaioli; Emanuele Ferrari; David Sulzer; Luigi Casella; Luigi Zecca
Journal:  Neurotox Res       Date:  2013-10-24       Impact factor: 3.911

5.  Dyspigmented hypertrophic scars: Beyond skin color.

Authors:  Abdulnaser Alkhalil; Bonnie C Carney; Taryn E Travis; Seid Muhie; Stacy Ann Miller; Jessica C Ramella-Roman; Pehman Ghassemi; Rasha Hammamieh; Marti Jett; Lauren T Moffatt; Jeffrey W Shupp
Journal:  Pigment Cell Melanoma Res       Date:  2019-04-05       Impact factor: 4.693

Review 6.  Proteomics in Human Parkinson's Disease: Present Scenario and Future Directions.

Authors:  Anubhuti Dixit; Rachna Mehta; Abhishek Kumar Singh
Journal:  Cell Mol Neurobiol       Date:  2019-06-12       Impact factor: 5.046

Review 7.  The role of oxidative stress in Parkinson's disease.

Authors:  Vera Dias; Eunsung Junn; M Maral Mouradian
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

8.  Saturation Binding of Nicotine to Synthetic Neuromelanin Demonstrated by Fluorescence Spectroscopy.

Authors:  Robert L Haining; Travis M Jones; Aubrey Hernandez
Journal:  Neurochem Res       Date:  2016-09-23       Impact factor: 3.996

Review 9.  Mitochondria in neurodegenerative disorders: regulation of the redox state and death signaling leading to neuronal death and survival.

Authors:  Makoto Naoi; Wakako Maruyama; Hong Yi; Keiko Inaba; Yukihiro Akao; Masayo Shamoto-Nagai
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.